Tirzepatide vs Semaglutide: Differences in Dosing, Side Effects, and Results

Tirzepatide (sold as Mounjaro and Zepbound) is a dual GLP-1 and GIP receptor agonist, while semaglutide (Ozempic and Wegovy) acts only on the GLP-1 receptor. In head-to-head trials like SURMOUNT and SURPASS, tirzepatide has shown larger average weight loss and A1C reductions than semaglutide, though individual response varies and both are well-studied options your doctor may recommend.

How the two medications actually work

GLP-1 (glucagon-like peptide-1) is a gut hormone that slows stomach emptying, blunts appetite, and helps the pancreas release insulin. Semaglutide mimics GLP-1 alone. Tirzepatide does that plus mimics GIP (glucose-dependent insulinotropic polypeptide), a second gut hormone that also influences how your body handles food and fat. Many endocrinologists believe the dual action is why tirzepatide tends to produce stronger metabolic effects, but research into the exact mechanism is still evolving.

Both are once-weekly subcutaneous injections, typically given in the abdomen, thigh, or upper arm, and both require slow dose titration to manage gastrointestinal side effects.

Dosing schedules at a glance

Semaglutide for weight loss (Wegovy) typically titrates monthly: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg. Ozempic for type 2 diabetes follows a similar ramp but caps at 2.0 mg.

Tirzepatide titrates monthly through 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. Many users report finding a "sweet spot" dose somewhere in the middle of that range where appetite suppression is meaningful but side effects stay tolerable.

Some patients and clinicians experiment with extended titration schedules — staying on a dose for six to eight weeks instead of four — to reduce nausea. This is something to discuss with your prescriber, not something to do on your own.

Side effects users commonly report

Both drugs share a similar side effect profile: nausea, constipation, diarrhea, fatigue, and occasional injection site reactions. Many users report nausea is most pronounced in the first week after a dose increase and fades within a few days. Sulfur burps, reflux, and a "full after two bites" feeling are also frequently mentioned in patient communities.

Less common but more serious risks — pancreatitis, gallbladder issues, and thyroid concerns — are why these medications require a prescription and ongoing medical supervision. Always report new abdominal pain, persistent vomiting, or yellowing skin to your doctor.

Tracking progress without spreadsheets

Whether you're on tirzepatide or semaglutide, the data that matters is the same: weekly weight, dose, injection site, side effect severity, and how your appetite and energy feel day to day. Lab markers like A1C, fasting glucose, and lipid panel matter too if your doctor is monitoring metabolic health.

Trace is a private logbook that keeps all of this on your phone with Face ID protection — no cloud account, no shared database. You log a dose, rotate sites, snap a progress photo, and the timeline builds itself. It's a practical option if you'd rather not put medication data in a generic notes app.

Frequently Asked Questions

Is tirzepatide stronger than semaglutide?

Clinical trials suggest tirzepatide produces greater average weight loss and A1C reduction at maximum doses, but "stronger" depends on the person. Some people respond better to semaglutide, tolerate it better, or have insurance coverage that makes it the practical choice.

Can you switch between the two?

Many patients switch under medical supervision, often because of insurance, supply, side effects, or a plateau. Your doctor will typically restart the titration at a low dose of the new medication rather than matching the previous dose milligram for milligram.

Do you regain weight if you stop?

Studies on both medications show that most people regain a significant portion of lost weight within a year of stopping, because appetite signaling returns to baseline. This is why GLP-1 therapy is increasingly discussed as a long-term tool rather than a short course — a conversation worth having with your doctor before starting.